{
    "nctId": "NCT04857697",
    "briefTitle": "Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer",
    "officialTitle": "Engineering Gut Microbiome to Target Cancer-Immune Microenvironment in Breast and Lung Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 6,
    "primaryOutcomeMeasure": "Length and adherence of probiotics",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* \\>= 18 years of age\n* Histologically confirmed adenocarcinoma of the breast operable stage I-III or histologically confirmed carcinoma of the lung operable stage I-III will be enrolled prior to their definitive surgery\n* Patients must have adequate organ function\n* Patients must be willing to provide tissue, blood and stool samples for the research study\n\nExclusion Criteria:\n\n* Patients must not receive systemic neoadjuvant therapy\n* Patients must not have taken any probiotics in the past 30 days prior to the enrollment\n* Patients with autoimmune disease, immune deficiency such as human immunodeficiency virus (HIV), irritable bowel, known diverticulosis, and other serious gastrointestinal (GI) conditions at treating physician's discretion will be excluded",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}